Innovative tissue, cell and gene therapies (also known as ATMP) play a considerable role in the evolution of new medicines. Yet, developers require clarity and advice in order to navigate the regulatory hurdles and achieve marketing authorization.
Proud to bring inspirational speakers from across the globe.
Director, Principal Consultant Innovative Therapies, PharmaLex
Dr. Buljovcic is a Biologist and has 15 years of experience working in the Regulatory Affairs business, including 10 years specializing in Tissue, Cell and Gene therapies. She has successfully supported various companies and academia in their development up to marketing authorization. She also provides regular public seminars and in-house trainings.